TrialFrontiers in immunology2022

Robust humoral and cellular recall responses to AZD1222 attenuate breakthrough SARS-CoV-2 infection compared to unvaccinated.

Jill Maaske et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.